July 19, 2023
This study is for patients who have untreated, early-stage HER2-positive breast cancer
January 5, 2023
The TAILORx trial in over 10,000 women with early breast cancer reaches 12 years of recurrence and survival outcomes
September 26, 2022
Robin Evans, a research advocate with the ECOG-ACRIN Cancer Research Group, shares her perspective on navigating the survivorship community as someone living with stage 4 cancer
September 26, 2022
Summaries of recently reported ECOG-ACRIN research results